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Abstract
Objective
Mental Retardation (MR) or Intellectual Disability is one of three chronic and 
disabling neurological disorders of children and adolescents. Its prevalence is 
estimated 1-3% of the population. MR is defined as significant sub-average 
intellectual functioning and adaptive behavior that become detectable before 
the age of 18. MR may come into view before 5 years as delay in at least two 
developmental domains which is called Global Developmental Delay (GDD). 
The causes of mental retardation can be considered under the titles of prenatal, 
perinatal and postnatal factors. Prenatal causes account for approximately 60 
-80 % of the etiological factors. All patients with GDD / MR should undergo a 
stepwise diagnostic approach, because a specific diagnosis leads to opportunity 
for treatment, future planning and genetic counseling. History, physical 
examination and neurodevelopmental examinations are the most important 
parts of the approach. Recent advances in cytogenetic investigations and 
neuroimaging studies have led to recognition of new disorders and improvement 
of the diagnostic yield. 
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Introduction
Definitions and classifications
Developmental disabilities are a group of interrelated, static neurologic disorders 
occurring in childhood and are expected to affect 5 % to 10 % of the children (1). 
Development can be divided into three major domains or skill areas (cognitive, 
motor, social and adaptive). Mental retardation (MR) is one of developmental 
disabilities at cognitive domains. Other terminologies that have been used instead 
of mental retardation are Mental Deficiency, Cognitive Deficiency, Mental 
Subnormality, Feeble-Mindedness, Mental Handicap, Oligophrenia, Idiocy, 
Amentia and Intellectual Disability. More recently, intellectual disability has been 
suggested to replace mental retardation (2). 
Tredgold has defined mental deficiency as a state of arrested or incomplete 
development of the mind. World Health Organization (WHO) defines mental 
retardation as an incomplete or insufficient general development of mental capacities 
(3).
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV), has defined mental retardation as “significantly sub-average intellectual 
function, existing concurrently with deficits in adaptive behavior and manifest 
during the developmental period” (4).   
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The American Association on Mental retardation 
(AAMR) defines mental retardation as follows:  “Mental 
retardation refers to substantial limitations in present 
functioning. It is characterized by significantly sub-
average intellectual functioning, existing concurrently 
with related limitations in two or more of the following 
applicable adaptive skill areas: communication, self-
care, home living, social skills, community use, self 
direction, health and safety, functional academics, 
leisure and work “(5). These findings must be evident 
before the age of 18 years (5). Significantly sub-average 
intellectual functioning means an Intelligence Quotient 
(IQ) score of 2 or more standard deviation below the 
mean (less than 68 on the Stanford-Binet or less than 70 
on the Wechsler test). 
Global Developmental Delay (GDD) is a subset of 
developmental disabilities defined as “a significant 
delay in two or more of the following developmental 
domains: gross/fine motor, speech/language, cognition, 
social/personal and activities of daily living” (6). The 
term GDD is usually reserved for children younger than 
five years old whereas the term MR is usually applied to 
older children when IQ testing is more valid and reliable 
(1).  
The degrees of mental retardation are expressed in 
various terms. DSMIV presents four types of MR, 
according to the degree of IQ level as mild (IQ:50-
70), moderate (IQ:36-50), severe (20-35) and profound 
(less than 20) (7). American Association on Mental 
Retardation focuses on the pattern or intensity of 
supports needed as intermittent, limited, extensive and 
pervasive or complete (8). When discussing the etiology 
and likelihood of a specific etiology, it is convenient to 
divide MR into mild and severe categories:
Mild mental retardation (IQ:50–70) occurs in 30/1000 
persons with an identifiable cause found in up to 50% 
while severe mental retardation (IQ:<50) occurs in 
3-4/1000 persons with an identifiable cause detected in 
70–80 % of the cases . 
Epidemiology of mental retardation
The prevalence of mental retardation at any time is 
estimated to be about 1 percent of the population (9), 
although cohorts defined only by IQ range from 2% to 
3%.  
As mentioned earlier, mild mental retardations is 10-12 
times more common than severe mental retardation.
Mental retardation is found more commonly in boys 
than girls in a 1.4:1 ratio (10), but ranges from 1.3 to 1.9: 
1 (11). This difference may be due to the presence of 
X-linked mental retardations. Severe to profound mental 
retardation presents as developmental delay before 5 
years of age, but mild mental retardation presents as 
academic dysfunction. 
Etiology
Hereditary and environmental factors may have a role in 
the etiology of mental retardation. Parents seek to know 
the etiology of their child’s developmental disabilities. 
In many cases of mental retardation, especially in mild 
cases, etiological diagnosis cannot be confirmed even 
after complete investigations. Etiological diagnosis is 
important because in some patients, a treatable cause 
may be present or genetic factors assist parents for 
further pregnancy or prediction. The causes of mental 
retardation can be considered under the headings of 
prenatal, perinatal and postnatal factors. 
Prenatal causes account for approximately 60-80 
% of the etiological factors and may be genetic or 
non-genetic (12). Genetic causes can be divided into 
chromosomal disorders and non-chromosomal genetic 
conditions. Dysmorphic features and presence of 
other malformations such as eyes, nose, mouth, heart, 
lung, genitourinary and skeleton, in addition to mental 
retardation, suggest chromosomal disorders .  
Down syndrome, with an incidence of 1 in 600 newborns, 
is the most common identifiable genetic cause of mental 
retardation and constitutes 4-7 % of all cases (13). Other 
chromosomal aberrations are various forms of trisomy, 
deletion syndromes  (Cat-cry, Prader-willi, Angelman), 
X chromosome abnormalities and Fragile X Syndrome. 
Fragile X Syndrome is the most common inherited 
cause of mental retardation. Fragile X Syndrome is 
widespread in humans and its frequency may be higher 
in some ethnic groups, such as Tunisian Jews and 
African- Americans (14;15). Speech delay, autistic like 
behavior and hyperactivity are often the presenting 
symptoms. Long facies, large ears and macroorchidism 
are suggestive signs.  
Non-chromosomal genetic conditions can be divided 
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as phakomatosis or neurocutaneous syndromes, Inborn 
Errors of Metabolism (IEM) and some structural brain 
abnormalities. The neurocutaneous syndromes such as 
tuberous sclerosis and neurofibromatosis are autosomal 
dominant. Other inheritance patterns and sporadic cases 
are present in the phakomatosis. Many IEMs including 
aminoacidopathies, organic acidemias, urea cycle 
disorders and lysosomal storage diseases are associated 
with intellectual disability. Newer IEMs are serine 
defects, creatine deficiency and glucose transporter 
deficiency (16). Many structural brain abnormalities are 
associated with mental retardation and sometimes other 
congenital anomalies. 
Non-genetic prenatal conditions consist of conditions 
such as environmental factors, maternal infections, 
antepartum hemorrhage and toxemia of pregnancy. 
Perinatal causes have been responsible for 10- 20 % of 
cases and includes neonatal asphyxia, prematurity and 
birth trauma (12). 
Postnatal causes such as meningitis and encephalitis, 
trauma, malnutrition, poverty, psychosocial deprivation 
and lead poisoning account for up to 10 percent of the 
cases (12).
Diagnostic categories of mental retardation are showed 
in Table 1 (17;18). 
Table 1: Causes of mental retardation by diagnostic 
category (17, 18)
Chromosomal abnormalities 4-28 %
Recognizable Syndromes 3-9 %
Structural brain abnormalities 3-17 %
Complications of prematurity 2-10 %
Perinatal conditions 8-13 %
Environmental / Teratogenic causes 5-13 %
Cultural / Familial mental retardation 3-12 %
Metabolic / Endocrine Causes 1-5 %
Unknown 30-50 %
Diagnostic evaluation of GDD / MR
“There is consensus that the history and the physical 
examination are the most important aspects of the 
investigation. An accurate prenatal/birth and hereditary/
familial history, in addition to a three-generation 
pedigree, is an essential step in the diagnostic evaluation 
of GDD / MR” (19). A detailed family history including 
mother’s previous gestational history, intrauterine 
problems, intrauterine toxin or radiation exposure, 
neonatal birth weight and head circumference, Apgar 
score, and the duration of hospital stay and the timing of 
the developmental milestones should be recorded. Head 
holding, rolling, crawling, sitting, standing, walking, 
babbling, first distinct words, two-word phrases and 
use of sentence are among the most important motor 
and language skills that must be recorded (20). The 
possibility of any loss or regression of previously 
acquired skills must be addressed as well as the age and 
reason for initial parental concern (20).    
A thorough physical examination including skin, 
abdomen for organomegaly, spine, minor anomalies 
and neurodevelopmental assessment can help either in 
making a diagnosis or in directing laboratory testing. 
The head shape, fontanels status and the current head 
circumference should be plotted. Amelanotic nevi, 
adenoma sebaceum , café au lait spots, diffuse dermal 
melanocytosis and ichthyosis are some examples of skin 
findings that suggest a specific diagnosis. Extensive 
Mongolian spots or diffuse dermal melanocytosis may be 
a clue to some neurometabolic disorders such as Hurler, 
GM1 gangliosidosis and Niemann-pick disease (21). 
Congenital ichthyosis may be associated with Sjogren-
Larsson syndrome (22). Shaefer and Bodensteiner 
state that the association of intellectual disability and 
congenital malformations has long been recognized and 
that a necessary component of the evaluation of a child 
with idiopathic intellectual disability is a comprehensive 
dysmorphologic examination (23).
Van Karnebeek, in a prospective study of the diagnostic 
evaluation of the developmental delay or intellectual 
disability of 281 children, found an etiologic diagnosis 
in 150 cases. One third of these diagnoses were made 
on the basis of the history and examination alone; in 
another one third, the history and examination provided 
essential clues to the diagnosis, and laboratory studies 
alone provided diagnosis in the remaining one third (24). 
This study found that based on clinical history alone, a 
diagnosis could be established in 1 of 20 patients, and 
based on physical examination alone, 1 in 30 patients 
could be diagnosed. Based on the combination of history 
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and examination together, 1 in 3 patients were diagnosed 
(24). Diagnostic yield of neurologic examination in the 
evaluation of intellectual disability is reported as 42.9 % 
(6,24). 
Intellectual assessment, adaptive evaluation, audiometry, 
vision testing, psychiatric and behavioral assessment are 
essential for diagnosis and evaluation of GDD/MR.
Recent technological advances in cytogenetic analysis 
and imaging have increased the potential for diagnostic 
yield.
Cytogenetics: “The yield of cytogenetic testing has 
been enhanced by recent advances including higher 
resolution banding, fluorescent in situ hybridization 
(FISH) and chromosome painting” (20).  Chromosomal 
abnormalities are reported in 4-34 % of the patients 
with GDD / MR and cytogenetic analysis is regarded 
as a mainstay in the diagnostic process (19). In a 
retrospective review from Montreal Children’s Hospital, 
the laboratory test with the highest yield of abnormal 
results was chromosome analysis (25). Van Karnebeek et 
al believe that routine karyotype is a valuable technique 
in the diagnostic evaluation of GDD/MR (24). They 
state that there is a relationship between the number of 
minor anomalies and the likelihood of a chromosome 
abnormality; a higher number of anomalies (>6) indicates 
a significantly higher likelihood to find a chromosome 
abnormality (24). Shevell et al believe that routine 
cytogenetic analysis is indicated in the evaluation of 
GDD even in the absence of dysmorphic features (26). 
Curry recommends that “Fragile X testing be strongly 
considered in both males and females with unexplained 
intellectual disability especially in the presence of 
a positive family history, a consistent physical and 
behavioral phenotype and absence of major structural 
abnormalities” (27). Van Karnebeek recommends that 
all boys with an unexplained intellectual disability have 
molecular genetic testing for Fragile X syndrome but 
that routine testing of girls is not warranted unless there 
is a positive family history (24). With the identification 
of an expanded trinucleotide repeat in the FMR-1 gene at 
Xq27, the standard diagnostic test for Fragile X Syndrome 
is now the quantification of the size of the trinucleotide 
repeat by DNA techniques, such as PCR and southern 
blot. Four forms of the CGG trinucleotide repeat have 
been described: normal (6-40 repeats), intermediate 
(41-60 repeats), permutation (61-200 repeats) and full 
mutation (>200-230 repeats) (28). A small expansion 
or premutation is usually not associated with cognitive 
deficits. A larger expansion or full mutation is associated 
with Fragile X syndrome and is associated with typical 
features.
The consensus conference in 1997 suggested that 
whenever there is a temporary diagnosis of microdeletion 
syndrome, a focused FISH analysis may be the first step 
(27). 
About 50% of all structural chromosome abnormalities 
include the telomeric region. Many deletions of the 
telomeres are evident by standard techniques, and the 
syndromes caused by such deletions are often clinically 
identifiable; for example, cri du chat syndrome, which 
is caused by the deletion of the telomere of the short 
arm of chromosome 5 (29). FISH techniques have been 
applied to examine the subtelomeric regions of each 
chromosome for abnormalities that are known to cause 
intellectual disability (19). FISH studies make it possible 
to localize specific DNA sequences by fluorescent 
labeling metaphase or prometaphase chromosomes, 
thereby providing numerous new markers, such as 
Williams Syndrome (7q11.23), Prader-willi syndrome 
(15q 11-13), Angelman syndrome (15q 11-13) and 
Miller-Dieker (17p 13.3) . 
Hidden chromosomal rearrangements involving the 
telomeric portions have been described as being 
responsible for a significant proportion of unexplained 
MR and other congenital anomalies. Submicroscopic 
subtelomeric chromosome defects have been found 
in 6.5-7.4 % of children with moderate to severe MR 
(30,31).
Specific subtelomeric FISH probes have been developed 
for each of the 42 telomeric regions in the human 
genome. Subtelomeric probes are expensive and must 
be requested only when there is strong suspicion of 
chromosomal rearrangements according to clinical 
findings and/or the pattern of transmission in the family. 
De Vries et al concluded that “good indicators for 
subtelomeric defects are a family history of MR, prenatal 
onset growth retardation, postnatal poor growth or over 
growth, two or more facial dysmorphic features and one 
or more nonfacial dysmorphic features or congenital 
abnormalities” (19,32).
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Rett syndrome is one of the leading causes of GDD/ 
MR in females and is caused by mutations in the 
X-linked gene encoding methyl-CpG- binding protein 2 
(MECP2) (33-35). About 80% of the patients with Rett 
syndrome have MECP2 mutations, but this mutation 
may result in progressive neurological manifestations 
(36,37), nonprogressive encephalopathy in males (38), 
or even an Angelman-like phenotype (39), without 
the manifestations of Rett syndrome . In other words, 
MECP2 mutation is not necessarily lethal in males. 
Neuroimaging: The diagnostic yield of neuroimaging 
for the evaluation of GDD / MR has a wide variation 
from 9% to 80%, depending on the practice of newer 
techniques and additional clinical findings. With 
high resolution Computerized Tomography (CT) and 
Magnetic Resonance Imaging (MRI), positive findings 
can be found in 30-60 % of patients (40). When imaging 
is done for screening of GDD under 5 years of age, 
abnormal findings may be found in 13.9 %, but 3 times 
higher if there are focal neurologic signs or head growth 
abnormalities (28). CT contributes to the etiologic 
diagnosis of GDD in approximately 30% of children 
and MRI will reveal abnormalities in 48.6 to 65.5 % of 
children with GDD (28). Abnormal neurologic findings, 
an abnormal head size, unexpected changes in behavior 
and seizure disorder in addition to GDD/ MR significantly 
increase the diagnostic yield (26,40). Finding of the 
congenital brain malformations can help with etiologic 
diagnosis, prognosis and genetic counseling. The 
radiological findings of GDD/ MR include cerebral 
injury (periventricular leukomalacia, ventriculomegaly, 
hemorrhagic sequels, and congenital infections), cerebral 
malformations (corpus callosum agenesis, septooptic 
dysplasia, migrational abnormalities) and cerebral 
dysgenesis (40). Some minor cerebral dysgenesis that 
can be found with neuroimaging are cavum septum 
pellucidum, megacysterna magna and corpus callosum 
dysgenesis. In one study, cerebral dysgenesis was 
the most common identified cause of developmental 
delay (6). Cerebral cortical malformations are a major 
cause of developmental delay and epilepsy (41,42). 
Finding cerebral malformations on neuroimaging is not 
necessarily accompanied by GDD / MR; for example, 
we reported a case of subcortical band heterotopia 
associated with corpus callosum agenesis but without 
GDD (43).  Although CT scan remains the study of 
choice in intracranial calcification and craniosynostosis, 
MRI allows sensitive assessment of gray and white 
matter and cerebral posterior fossa contents. Proton MR 
Spectroscopy (MRS) is a newer technique that is proved 
to be useful in the diagnosis of some metabolic disorders 
presenting with GDD / MR (44).
“The diagnostic yield of metabolic studies, 
electroencephalogram, thyroid function testing and 
lead screening in children with isolated mild mental 
retardation (those without abnormalities on examination 
or diagnostic red flags in the history) is low” (28). 
Routine metabolic screening tests are not recommended 
in the evaluation of GDD/ MR because of its low 
diagnostic yield (45). Routine screening for IEM in 
children with GDD has a yield of about 1% and when 
screening is performed, the yield may increase to about 
14% (28). There was consensus that such tests should be 
selective and targeted. Parental consanguinity, affected 
sibling, congenital ataxia or dysequilibrium, epilepsy, 
developmental regression, prominent feeding difficulties, 
organomegaly and coarse facial feature merit  metabolic 
testing including blood gas, serum lactate and ammonia, 
serum aminoacid, carnitine, homocysteine and very long 
chain fatty acids and urine organic acids, orotic acid, 
glycosaminoglycans and oligasaccharides (6).
Phenylketonuria (PKU) is one of the inborn errors of 
metabolism (IEM) that needs early diagnosis to prevent 
mental retardation, although even early diagnosis and 
treatment cannot prevent executive dysfunction (46,47). 
Biotinidase deficiency is a treatable IEM that may 
present with GDD without other symptoms or signs. 
Early diagnosis and treatment of Biotinidase deficiency 
improves outcome; therefore, in many countries, this 
disorder is screened routinely in the neonatal period (48). 
Electroencephalography (EEG) is useful in the 
evaluation of developmental delay, principally in 
association with seizure disorder or speech regression 
suggestive of Landau-Kleffner syndrome (6,17,28,42). 
An EEG is recommended when a child with GDD/ MR 
has a history of epilepsy, epileptic syndrome or speech 
regression (28). 
There is evidence that children with developmental delay 
may have significantly higher blood Lead concentration 
than normal children (49); therefore, some investigators 
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recommend Lead level testing as the first line screening 
tests (50). The North American Recommendations 
suggest that Lead screening should be targeted for those 
with risk factors for lead exposure (28). Approximately 
10 % of the children with developmental delay and 
identifiable risk factors for excessive environmental 
Lead exposure may have an elevated Lead level (28). 
McDonald et al also recommend thyroid function tests 
(TFT) as first line screening tests due to the importance 
of early treatment and its accompaniment to some 
chromosomal abnormalities such as Down syndrome 
and Turner syndrome (50). In the absence of newborn 
screening, congenital hypothyroidism may be responsible 
for approximately 4 % of cases of developmental delay 
(28). 
Furthermore, the North American Recommendations 
suggest TFT only if there are systemic features of 
hypothyroidism (28). 
Calcium assay will assist in the diagnosis and 
management of conditions like DiGeorge syndrome, 
Williams’s syndrome and pseudohypoparathyroidism 
(51). Iron deficiency can be associated with 
developmental delay, and therefore its measurement is 
recommended (52). Diagnostic yield of investigations in 
children with developmental delay are shown in Table 
2 (28).  
Clinical Pitfalls in the diagnosis of mental retardation: 
Variations of normal development and pseudo-
retardation are the main pitfalls in the diagnosis of mental 
retardation. Variations of normal development and the 
wide range of its achievement may cause diagnostic 
errors, if the physician is not familiar with them. For 
example, Bottom-shufflers are a group of normal 
children that show delay in weight-bearing and walking 
and replace crawling. Excessive reliance on gross motor 
milestones may cause missing of mental retardation 
diagnosis in children with normal motor milestones. 
Lack of opportunity and stimulation in a normal child, 
children with severe medical illnesses, deafness or poor 
vision, severe physical handicap and infantile autism are 
main causes of pseudo-retardation. 
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